Freeze, then boost: novel combo could spare bladders from removal

NCT ID NCT07204132

Recruiting now Disease control Sponsor: Changhai Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach to treat high-risk bladder cancer without removing the bladder. Doctors will first remove the tumor through the urethra, then freeze the tumor base with a special balloon, followed by immunotherapy and low-dose chemotherapy. The goal is to see if this combination can keep the cancer from coming back and help patients live longer, while preserving their bladder and quality of life. The trial plans to enroll 180 patients in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cryoablation (freezing) plus anti-PD-1 immunotherapy (e.g., Camrelizumab, Tislelizumab) and chemotherapy (Gemcitabine + Cisplatin)
What this could lead to: If successful, this could offer a less invasive, bladder-sparing treatment option that reduces recurrence and improves survival for patients with high-risk bladder cancer.
What could go wrong: This is an early-stage, non-randomized study with only 180 patients, so results may not apply broadly. The combination therapy also carries risks of side effects from immunotherapy and chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

superficial urinary bladder carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

ChangHai Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.